Advertisement
Screener

TherapeuticsMD, Inc. (TXMD) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

TherapeuticsMD, Inc. Operating Cash Flow

TherapeuticsMD, Inc. (TXMD) reported Operating Cash Flow of -$8.70 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.

Discontinued › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2023-05-15

  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for the quarter ending 2023-03-31 was -$8.70M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for the quarter ending 2022-09-30 was -$18.92M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for the quarter ending 2022-06-30 was -$27.06M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for the quarter ending 2022-03-31 was -$17.87M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for fiscal 2021 was -$142.69M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for fiscal 2020 was -$159.47M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for fiscal 2019 was -$165.72M.
  • TherapeuticsMD, Inc. net cash provided by (used in) operating activities for fiscal 2018 was -$106.81M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2023-03-31-$8.70M
10-Q · filed 2023-05-15
2022-09-30-$18.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$45.98M
derived: sum of 2 quarters · filed 2022-11-14
-$63.85M
10-Q · filed 2022-11-14
-$103.41M
derived: sum of 4 quarters · filed 2023-05-15
2022-06-30-$27.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$44.93M
10-Q · filed 2022-08-15
-$84.49M
derived: sum of 3 quarters · filed 2023-05-15
-$122.71M
derived: sum of 4 quarters · filed 2023-05-15
2022-03-31-$17.87M
10-Q · filed 2023-05-15
-$29.53M
10-Q · filed 2022-05-16
-$57.43M
derived: sum of 2 quarters · filed 2023-05-15
-$95.65M
derived: sum of 3 quarters · filed 2023-05-15
-$122.19M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$39.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
-$77.78M
derived: sum of 2 quarters · filed 2022-11-14
-$104.31M
derived: sum of 3 quarters · filed 2022-11-14
-$142.69M
10-K · filed 2022-03-23
2021-09-30-$38.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$64.75M
derived: sum of 2 quarters · filed 2022-11-14
-$103.14M
10-Q · filed 2022-11-14
-$133.49M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$26.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$64.91M
10-Q · filed 2022-08-15
-$95.27M
derived: sum of 3 quarters · filed 2022-08-15
-$129.32M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31-$38.38M
10-Q · filed 2022-05-16
-$68.74M
derived: sum of 2 quarters · filed 2022-05-16
-$102.79M
derived: sum of 3 quarters · filed 2022-05-16
-$158.74M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31-$30.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
-$64.41M
derived: sum of 2 quarters · filed 2022-03-23
-$120.36M
derived: sum of 3 quarters · filed 2022-03-23
-$159.47M
10-K · filed 2022-03-23
-$159.47M
10-K · filed 2021-03-04
2020-09-30-$34.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$90.00M
derived: sum of 2 quarters · filed 2021-11-12
-$129.11M
10-Q · filed 2021-11-12
-$129.15M
10-Q · filed 2020-11-09
-$179.93M
derived: sum of 4 quarters · filed 2022-03-23
2020-06-30-$55.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
-$95.06M
10-Q · filed 2021-08-04
-$95.10M
10-Q · filed 2020-08-07
-$145.88M
derived: sum of 3 quarters · filed 2022-03-23
-$172.11M
derived: sum of 4 quarters · filed 2022-03-23
2020-03-31-$39.11M
10-Q · filed 2021-05-06
-$39.11M
10-Q · filed 2020-05-06
-$89.93M
derived: sum of 2 quarters · filed 2022-03-23
-$116.15M
derived: sum of 3 quarters · filed 2022-03-23
-$166.67M
derived: sum of 4 quarters · filed 2022-03-23
2019-12-31-$50.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
-$77.04M
derived: sum of 2 quarters · filed 2022-03-23
-$127.55M
derived: sum of 3 quarters · filed 2022-03-23
-$165.72M
10-K · filed 2022-03-23
-$165.70M
10-K · filed 2020-02-24
2019-09-30-$26.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$76.74M
derived: sum of 2 quarters · filed 2020-11-09
-$114.90M
10-Q · filed 2020-11-09
-$143.05M
derived: sum of 4 quarters · filed 2021-03-04
2019-06-30-$50.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
-$88.68M
10-Q · filed 2020-08-07
-$116.82M
derived: sum of 3 quarters · filed 2021-03-04
-$150.89M
derived: sum of 4 quarters · filed 2021-03-04
2019-03-31-$38.16M
10-Q · filed 2020-05-06
-$66.31M
derived: sum of 2 quarters · filed 2021-03-04
-$100.38M
derived: sum of 3 quarters · filed 2021-03-04
-$125.33M
derived: sum of 4 quarters · filed 2021-03-04
2018-12-31-$28.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
-$62.21M
derived: sum of 2 quarters · filed 2021-03-04
-$87.16M
derived: sum of 3 quarters · filed 2021-03-04
-$106.81M
10-K · filed 2021-03-04
2018-09-30-$34.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
-$59.02M
derived: sum of 2 quarters · filed 2019-11-08
-$78.67M
10-Q · filed 2019-11-08
-$99.47M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30-$24.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$44.60M
10-Q · filed 2019-08-09
-$65.40M
derived: sum of 3 quarters · filed 2020-02-24
-$82.09M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31-$19.65M
10-Q · filed 2019-05-08
-$40.46M
derived: sum of 2 quarters · filed 2020-02-24
-$57.14M
derived: sum of 3 quarters · filed 2020-02-24
-$75.28M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31-$20.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
-$37.49M
derived: sum of 2 quarters · filed 2020-02-24
-$55.63M
derived: sum of 3 quarters · filed 2020-02-24
-$76.16M
10-K · filed 2020-02-24
2017-09-30-$16.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$34.82M
derived: sum of 2 quarters · filed 2018-11-08
-$55.35M
10-Q · filed 2018-11-08
-$70.97M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30-$18.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30
-$38.67M
10-Q · filed 2018-07-30
-$54.28M
derived: sum of 3 quarters · filed 2019-02-27
-$73.08M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31-$20.53M
10-Q · filed 2018-05-07
-$36.14M
derived: sum of 2 quarters · filed 2019-02-27
-$54.94M
derived: sum of 3 quarters · filed 2019-02-27
-$70.26M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31-$15.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
-$34.42M
derived: sum of 2 quarters · filed 2019-02-27
-$49.74M
derived: sum of 3 quarters · filed 2019-02-27
-$69.14M
10-K · filed 2019-02-27
2016-09-30-$18.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
-$34.12M
derived: sum of 2 quarters · filed 2017-11-07
-$53.52M
10-Q · filed 2017-11-07
-$70.13M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30-$15.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
-$34.73M
10-Q · filed 2017-08-03
-$51.33M
derived: sum of 3 quarters · filed 2018-02-23
-$69.77M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31-$19.40M
10-Q · filed 2017-05-03
-$36.01M
derived: sum of 2 quarters · filed 2018-02-23
-$54.45M
derived: sum of 3 quarters · filed 2018-02-23
-$79.30M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31-$16.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
-$35.05M
derived: sum of 2 quarters · filed 2018-02-23
-$59.89M
derived: sum of 3 quarters · filed 2018-02-23
-$79.04M
10-K · filed 2018-02-23
2015-09-30-$18.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04
-$43.28M
derived: sum of 2 quarters · filed 2016-11-04
-$62.43M
10-Q · filed 2016-11-04
-$77.72M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30-$24.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
-$44.00M
10-Q · filed 2016-08-05
-$59.28M
derived: sum of 3 quarters · filed 2017-02-28
-$70.74M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31-$19.15M
10-Q · filed 2016-05-05
-$34.43M
derived: sum of 2 quarters · filed 2017-02-28
-$45.89M
derived: sum of 3 quarters · filed 2017-02-28
-$55.96M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31-$15.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$26.74M
derived: sum of 2 quarters · filed 2017-02-28
-$36.82M
derived: sum of 3 quarters · filed 2017-02-28
-$45.52M
10-K · filed 2017-02-28
2014-09-30-$11.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
-$21.53M
derived: sum of 2 quarters · filed 2015-11-05
-$30.24M
10-Q · filed 2015-11-05
-$35.00M
derived: sum of 4 quarters · filed 2016-02-26
2014-06-30-$10.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07
-$18.78M
10-Q · filed 2015-08-07
-$23.55M
derived: sum of 3 quarters · filed 2016-02-26
-$28.86M
derived: sum of 4 quarters · filed 2016-02-26
2014-03-31-$8.71M
10-Q · filed 2015-05-07
-$13.47M
derived: sum of 2 quarters · filed 2016-02-26
-$18.79M
derived: sum of 3 quarters · filed 2016-02-26
-$25.97M
derived: sum of 4 quarters · filed 2016-02-26
2013-12-31-$4.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26
-$10.08M
derived: sum of 2 quarters · filed 2016-02-26
-$17.26M
derived: sum of 3 quarters · filed 2016-02-26
-$20.77M
10-K · filed 2016-02-26
2013-09-30-$5.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07
-$12.49M
derived: sum of 2 quarters · filed 2014-11-07
-$16.00M
10-Q · filed 2014-11-07
-$15.89M
10-Q · filed 2013-11-05
-$20.01M
derived: sum of 4 quarters · filed 2015-03-12
2013-06-30-$7.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$10.68M
10-Q · filed 2014-08-07
-$14.69M
derived: sum of 3 quarters · filed 2015-03-12
-$17.77M
derived: sum of 4 quarters · filed 2015-03-12
2013-03-31-$3.51M
10-Q · filed 2014-05-07
-$7.52M
derived: sum of 2 quarters · filed 2015-03-12
-$10.60M
derived: sum of 3 quarters · filed 2015-03-12
-$13.79M
derived: sum of 4 quarters · filed 2015-03-12
2012-12-31-$4.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
-$7.09M
derived: sum of 2 quarters · filed 2015-03-12
-$10.29M
derived: sum of 3 quarters · filed 2015-03-12
-$12.74M
10-K · filed 2015-03-12
2012-09-30-$3.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05
-$6.28M
derived: sum of 2 quarters · filed 2013-11-05
-$8.73M
10-Q · filed 2013-11-05
-$8.40M
10-Q · filed 2012-11-13
-$10.62M
derived: sum of 4 quarters · filed 2014-03-05
2012-06-30-$3.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
-$5.65M
10-Q · filed 2013-08-07
-$5.25M
10-Q · filed 2012-08-09
-$7.53M
derived: sum of 3 quarters · filed 2014-03-05
-$9.05M
derived: sum of 4 quarters · filed 2014-03-05
2012-03-31-$2.45M
10-Q · filed 2013-05-10
-$4.34M
derived: sum of 2 quarters · filed 2014-03-05
-$5.86M
derived: sum of 3 quarters · filed 2014-03-05
-$6.66M
derived: sum of 4 quarters · filed 2014-03-05
2011-12-31-$1.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-05
-$3.40M
derived: sum of 2 quarters · filed 2014-03-05
-$4.21M
derived: sum of 3 quarters · filed 2014-03-05
-$4.97M
10-K · filed 2014-03-05
2011-09-30-$1.52M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13
-$2.32M
derived: sum of 2 quarters · filed 2012-11-13
-$3.08M
10-Q · filed 2012-11-13
-$202.17K
10-Q · filed 2011-11-07
2011-06-30-$801.78K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$1.56M
10-Q · filed 2012-08-09
-$146.95K
10-Q · filed 2011-08-15
2011-03-31-$760.74K
10-Q · filed 2012-05-11
2010-09-30$411.53K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07
$30.60K
10-Q · filed 2011-11-07
2010-06-30-$380.93K
10-Q · filed 2011-08-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
NextCure, Inc. (NXTC)United States$0.024B-0.15
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Cocrystal Pharma, Inc. (COCP)United States$0.022B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86